Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized placebo-controlled study of SGC001 in predicted severe acute pancreatitis
ChiCTR2600135359Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of SGC001 in acute pancreatitis (AP) (4 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Safety indicators and Days alive without organ failure within 14 days post-randomization. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
SGC001
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on ChiCTR2600135359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135359.